DATA COLLECTIVE IV GP LLC
Q3 2026 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001664974
· Institutional investment manager
$63.3M Reported Value Total
Reported value
$63.3M
Quarter over quarter
-19.4%
Holdings
4
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Spencer Punter
Authorized Signatory
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $63.3M |
| Positions | 4 |
| Change in reported value | -19.4% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
4 | $63.3M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
4 | $78.6M |
|
Q1 2026 13F
Filed May 15, 2026
|
4 | $55.9M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
3 | $58.5M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
4 | $68.0M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
5 | $129.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
5 | $86.9M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
6 | $226.3M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
6 | $163.5M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $142.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
5 | $115.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
5 | $120.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
5 | $105.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
6 | $135.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
6 | $93.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
6 | $95.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
5 | $126.5M |
|
Q2 2022 13F
Filed Nov 14, 2022
|
5 | $121.1M |
|
Q1 2022 13F
Filed Nov 14, 2022
|
5 | $471.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
5 | $740.7M |
Top 4 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RXRX Recursion Pharmaceuticals, Inc. | $24.5M | 38.76% |
| 2 | EVLV Evolv Technologies Holdings, Inc. | $21.3M | 33.72% |
| 3 | HQ Horizon Quantum Holdings Ltd | $13.6M | 21.48% |
| 4 | DFTX Definium Therapeutics, Inc. (MindMed) | $3.8M | 6.03% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.